Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2016

View Archived Issues

Scientists identify methylated regions associated with hand osteoarthritis

Cellectar Biosciences reports updated results from phase I study of CLR-131

Signature Therapeutics initiates phase I study of PF-614

Bristol-Myers Squibb initiates phase I/IIa study of BMS-986207

ACADIA Pharmaceuticals initiates phase II trial of pimavanserin for adjunctive therapy for MDD

GSK files MAA for once-daily closed triple combination therapy for patients with COPD

Novel CDC7 inhibitor TAK-931 demonstrates potent antitumor activity in vitro and in vivo

AiCuris begins phase II study of pritelivir

FDA accepts for review sBLA for Keytruda in classical Hodgkin's lymphoma

DiaMedica sells DM-71 and related IP

Opdivo approved in Japan for relapsed or refractory classical Hodgkin's lymphoma

First-in-human data reported for checkpoint inhibitor TTI-62 at ASH

Mochida obtains Japanese approval for Dinagest for adenomyosis

English NICE recommends use of pembrolizumab for advanced NSCLC

EMA committee confirms hepatitis B re-activation risk with direct-acting antivirals for hepatitis C

Kite Pharma initiates rolling BLA submission for KTE-C19

Merck & Co. to advance anti-CD27 agonist from Aduro collaboration

Amryt Pharma in-licenses European and Middle Eastern rights to Lojuxta

Phase III study of Shire's Vonvendi meets primary endpoint

Acetylon enters agreement to be acquired by Celgene, plans to launch spin-out

ReNeuron reports data from phase II trial of CTX cell therapy candidate for stroke disability

Preliminary phase I data from ZUMA-3 and ZUMA-4 studies of KTE-C19 presented

Cannabidivarin receives orphan designation for Rett syndrome in the U.S.

The Center Translational Drug Development patents novel Rho kinase inhibitors

Sun Pharma Advanced Research patents new tyrosine kinase inhibitors

Merck & Co. presents novel phosphodiesterase PDE2A inhibitors

Roche identifies new survival motor neuron protein 2 splicing modulators

Lilly patents novel DGAT-2 inhibitors

FDA approves new indication for Jardiance

Imbruvica approved for new indication in Japan

Cellular Biomedicine cleared in China to start phase I study of C-CAR-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...